Business Wire12.17.18
Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced that Steve MacKinnon has joined its senior management team as vice president of Sales, effective immediately. Reporting to the CEO, MacKinnon will oversee the creation of a U.S. based sales team and will play a central role in planning and executing the company’s projected launch of the Tack Endovascular System in 2019.
“Steve brings a stellar track record of sales achievement across a broad range of entrepreneurial medical technology companies,” said Bruce Shook, Intact Vascular’s president and CEO. “Steve’s experience with creating and motivating high performance sales teams, coupled with his deep knowledge of the peripheral vascular market, will be tremendous assets to us as we move toward launch of our flagship product next year.”
Prior to joining Intact Vascular, MacKinnon was the vice president of U.S. Sales for Neuronetics, where he significantly expanded the sales team and product revenue, and helped take the company public. Prior to Neuronetics, Steve served as vice president of U.S. Sales for Access Closure and was instrumental in its successful merger with Cardinal Health. He also held multiple sales positions with Fox Hollow Technologies prior to its sale to eV3.
“Intact Vascular represents an exciting opportunity to bring high-value innovations to peripheral vascular patients,” said Steve MacKinnon. “I look forward to building a world class sales organization at Intact and to a very successful launch of the Tack Endovascular System.”
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Pre-loaded with six self-expanding nitinol devices for above-the-knee (ATK) interventions, the Tack Endovascular System can be deployed to treat multiple dissections using a single catheter and leaving behind less than 70 percent less metal than stents.1 Additionally, the Tack Endovascular System offers low radial force, designed to promote healing, improve outcomes and preserve future treatment options for PAD and critical limb ischemia (CLI) patients.
References
1. Bosiers M, Scheinert D, Hendricks JMH et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg 2016;64:109-16.
“Steve brings a stellar track record of sales achievement across a broad range of entrepreneurial medical technology companies,” said Bruce Shook, Intact Vascular’s president and CEO. “Steve’s experience with creating and motivating high performance sales teams, coupled with his deep knowledge of the peripheral vascular market, will be tremendous assets to us as we move toward launch of our flagship product next year.”
Prior to joining Intact Vascular, MacKinnon was the vice president of U.S. Sales for Neuronetics, where he significantly expanded the sales team and product revenue, and helped take the company public. Prior to Neuronetics, Steve served as vice president of U.S. Sales for Access Closure and was instrumental in its successful merger with Cardinal Health. He also held multiple sales positions with Fox Hollow Technologies prior to its sale to eV3.
“Intact Vascular represents an exciting opportunity to bring high-value innovations to peripheral vascular patients,” said Steve MacKinnon. “I look forward to building a world class sales organization at Intact and to a very successful launch of the Tack Endovascular System.”
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Pre-loaded with six self-expanding nitinol devices for above-the-knee (ATK) interventions, the Tack Endovascular System can be deployed to treat multiple dissections using a single catheter and leaving behind less than 70 percent less metal than stents.1 Additionally, the Tack Endovascular System offers low radial force, designed to promote healing, improve outcomes and preserve future treatment options for PAD and critical limb ischemia (CLI) patients.
References
1. Bosiers M, Scheinert D, Hendricks JMH et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg 2016;64:109-16.